

[836-200-0515](#)

Threshold for Reporting Drug Price Increase

(1) No later than July 1, 2019, a reporting manufacturer must report the information described in OAR 836-200-053~~30(2)~~ to the department regarding each prescription drug for which:

- (a) The price at any point in 2018 was \$100 or more for a one-month supply; and
- (b) There was a net yearly increase of 10 percent or more in the price of the prescription drug described in subsection (a) of this section during 2018.

(2) Beginning ~~February-March 156~~, 2020~~4~~, no later than March 15 annually, a reporting manufacturer ~~may voluntarily~~**must** report to the department the information described in OAR 836-200-053~~30(2)~~ regarding each prescription drug for which:

- (a) The price at any point during the previous year was \$100 or more for a one-month supply; and
- (b) There was a net yearly increase of 10 percent or more in the price of the prescription drug described in subsection (a) of this section over the course of the previous calendar year.

Statutory/Other Authority: ORS 646A.689

Statutes/Other Implemented: ORS 646A.689

History:

[ID 1-2026, temporary amend filed 02/12/2026, effective 02/13/2026 through 08/11/2026](#)

[ID 2-2025, amend filed 03/26/2025, effective 04/01/2025](#)

[ID 2-2019, adopt filed 02/26/2019, effective 03/01/2019](#)

[836-200-0530](#)

Form and Manner Requirements for Drug Pricing Reporting

(1) General requirements. All reports submitted by drug manufacturers under ORS 646A.689 must:

- (a) Be provided in an electronic format specified by the department;
- (b) Be provided via an electronic system specified by the department;
- (c) Be machine readable;
- (d) Be capable of being reduced to written form;

Commented [SL1]: Making the 2026 temporary rules permanent and updating citations

(e) Clearly indicate the information the manufacturer asserts to be conditionally exempt from disclosure under ORS 192.345 as a trade secret in adherence with OAR 836-200-0540;

(f) Include a certification of compliance document certifying that the filing complies with all applicable Oregon statutes, rules, standards and filing requirements; and

(g) Adhere to the standards set forth on the department's website.

836-200-0533

Prescription Drug Reporting – Annual Price Increase

~~(2) Prescription Drug Reporting – Price Increase.~~ For drugs meeting the conditions specified in OAR 836-200-0515, ~~the~~ report ~~may be voluntarily~~ furnished to the department ~~and must~~ include the following information, along with any documentation to support the information reported under this section:

~~(1a)~~ The full trade name of the drug, full chemical name or biologic product name of the drug, and recognized industry standard drug identification information for the drug as specified on the department's website;

~~(2b)~~ The price of the drug at the beginning ~~and the end~~ of the ~~calendar-reporting~~ year ~~preceding the report~~;

~~(3e)~~ The price of the drug at the ~~beginning and the~~ end of the calendar year preceding the ~~reporting year~~;

~~(4d)~~ ~~The price, and associated date, of the drug for each price change during the reporting year, if applicable;~~

~~(5)~~ The ~~highest and lowest~~ price, ~~and associated date,s~~ of the drug ~~for each price change at any point~~ during the calendar year preceding the report~~ing year, if applicable;~~

~~(6e)~~ The ~~net yearly~~ increase ~~in the price of the drug for in the price of the drug over~~ the ~~reporting preceding calendar~~ year, expressed as a percentage;

~~(7f)~~ The ~~price and~~ dosage of the drug the reporting manufacturer used to determine that the drug cost \$100 or more for a one-month supply;

~~(8g)~~ The ~~length of time~~ ~~date and price when~~ the prescription drug ~~has been on first entered~~ the market ~~with approval from the U.S. Food and Drug Administration;~~

~~(9h)~~ ~~All The~~ factors that contributed to the price increase ~~in the reporting year, including a narrative description and explanation of all major financial and nonfinancial factors with~~

Commented [SL2]: Adding new section for the language from 836-200-0530(2)

Commented [SL3]: Making 2026 temporary rules permanent

[any associated impact or explanation](#), that influenced the decision to increase the wholesale acquisition cost of the drug product and to decide on the amount of the increase. [Factors may include, but are not limited to:](#)

[\(a\) Other prescription drugs, including the drug name, labeler name, and price;](#)

[\(b\) Changes to manufacturing costs for the prescription drug;](#)

[\(c\) Changes to marketing costs for the prescription drug;](#)

[\(d\) Changes to distribution costs for the prescription drug;](#)

[\(e\) Changes to costs of ongoing safety and effectiveness research associated with the prescription drug;](#)

[\(f\) Other cost changes for the prescription drug; and](#)

[\(g\) Other cost changes not specifically associated with the prescription drug.](#)

[\(10i\)](#) The name of any generic version or biosimilar of the prescription drug available for sale in the United States at the time of the report;

[\(11j\)](#) The research and development costs associated with the prescription drug that were paid using public funds, including all available information about the sources and uses of these public funds;

[\(12k\)](#) The direct costs incurred and specific total dollars expended by the manufacturer in the [previous calendar reporting](#) year:

[\(aA\)](#) To manufacture the prescription drug;

[\(bB\)](#) To market the prescription drug, including spending on direct-to-consumer marketing such as paid advertising, as well as spending to promote the drug to [health care professionals-physicians](#);

[\(cC\)](#) To distribute the prescription drug; and

[\(dD\)](#) For ongoing safety and effectiveness research associated with the prescription drug.

[\(13t\)](#) The total sales revenue for the prescription drug during the [previous calendar reporting](#) year;

[\(14m\)](#) The manufacturer's net profit [or loss](#) attributable to the prescription drug during the [previous calendar reporting](#) year;

[\(n\)](#) [The introductory price of the prescription drug when it was approved for marketing by the United States Food and Drug Administration;](#)

[\(15e\)](#) The net yearly increase, if any, by calendar year, in the price of the prescription drug during the previous five calendar years;

(16~~p~~) The 10 highest prices paid for the prescription drug during the ~~previous~~ ~~calendar~~ ~~reporting~~ year in any country other than the United States, expressed in dollars according to the prevailing exchange rate at the time of the report; and

(17~~q~~) Any other information that the manufacturer deems relevant to the price increase and that the manufacturer deems will assist the director to complete a review of a drug price under ORS 646A.689.

Statutory/Other Authority: ORS 646A.689

Statutes/Other Implemented: ORS 646A.689

History:

[ID 1-2026, temporary amend filed 02/12/2026, effective 02/13/2026 through 08/11/2026](#)

[ID 2-2025, amend filed 03/26/2025, effective 04/01/2025](#)

[ID 2-2019, adopt filed 02/26/2019, effective 03/01/2019](#)

836-200-0532

Prescription Drug Reporting – Patient Assistance Programs

(1) If a reporting manufacturer offers one or more patient assistance programs to consumers residing in Oregon to reduce consumer out-of-pocket costs for a drug meeting the conditions specified in OAR 836-200-0515, the report furnished to the department under OAR 836-200-053~~30(2)~~ must have an appendix that includes at least the following information for each patient assistance program relevant to the drug that is the subject of the report:

(a) The number of consumers residing in Oregon who participated in the patient assistance program over the previous calendar year;

(b) The total dollar value of the coupons, discounts, copayment assistance or other reduction in costs provided to consumers residing in Oregon who participated in the patient assistance program over the previous calendar year;

(c) For each drug, the number of refills that qualify for the program, if applicable;

(d) If the program expires after a specified period of time, the period of time that the program is available to each consumer; and

(e) The eligibility criteria for the program and how eligibility is verified for accuracy.

(2) If a reporting manufacturer provides funding for an independent patient assistance program that reduces consumer out-of-pocket costs for a drug meeting the conditions specified in OAR 836-200-0515, the report furnished to the department under OAR 836-200-053~~30(2)~~ must have an appendix that provides the name of the independent program

and includes all of the information specified in section (1) that is available to the manufacturer at the time of the report. If the independent program provides services in addition to reducing consumer out-of-pocket costs for the drug that is the subject of the report, the manufacturer may limit the information provided to the information applicable to the drug that is the subject of the report. Reporting manufacturers that provide funding for independent patient assistance programs must act in good faith to secure this information.

(3) Reporting manufacturers that provide funding for a bona fide Independent Charity Patient Assistance Program operating in full compliance with the guidance provided in the Department of Health and Human Services Office of the Inspector General's Supplemental Special Advisory Bulletin: Independent Charity Patient Assistance Programs (Federal Register / Vol. 79, No. 104 / Friday, May 30, 2014 / Notices) are not required to include information about the bona fide Independent Charity Patient Assistance Program in any appendix required by this rule.

Statutory/Other Authority: ORS 646A.689

Statutes/Other Implemented: ORS 646A.689

History:

[ID 2-2025, adopt filed 03/26/2025, effective 04/01/2025](#)

836-200-0535

Additional Information Requests

(1) Within 60 calendar days of receiving a report from a prescription drug manufacturer in accordance with OAR 836-200-0515 to 836-200-053~~32~~, the director or director's designee may submit one or more written requests for supporting documentation or additional information to the manufacturer.

(2) The department's request shall be limited to information necessary to clarify or substantiate the material previously reported, or to enable the department to conduct an analysis of factors affecting drug prices for the purposes of providing recommendations to the Legislature as provided by ORS 646A.689.

(3) Within 60 calendar days of receiving the department's request for supporting documentation or additional information following a report provided in accordance with OAR 836-200-0515 to 836-200-053~~32~~, a prescription drug manufacturer must provide a full and complete written response, including any requested documentation. Supporting documentation or additional information submitted will be part of the report published to the department's website. If the manufacturer asserts that any of the requested information is conditionally exempt from disclosure as a trade secret, the manufacturer

must clearly identify the information claimed as trade secret and provide an explanation, as specified under OAR 836-200-0540, for each piece of information that is claimed to be exempt from disclosure.

(4) If additional time is needed, within 15 calendar days of receiving the department's request for supporting documentation or additional information following a report provided in accordance with ORS 646A.689 and OAR 836-200-0515 to 836-200-05332, a prescription drug manufacturer must submit a notice to the department for up to 30 additional days to prepare and submit a response. A drug manufacturer's request for additional time must be in writing, and must explain the grounds for the request and the need for additional time to prepare a response. The department will automatically grant requests submitted in accordance with this section.

Statutory/Other Authority: ORS 646A.689

Statutes/Other Implemented: ORS 646A.689

History:

[ID 2-2025, amend filed 03/26/2025, effective 04/01/2025](#)

[ID 2-2019, adopt filed 02/26/2019, effective 03/01/2019](#)

836-200-0545

Public Disclosure of Prescription Drug Manufacturer Filings

(1) As soon as practicable after receiving a filing from a prescription drug manufacturer under OAR 836-200-0530 to 836-200-05332, the department shall post to its website the name of the manufacturer and the prescription drug that is the subject of the filing.

(2) Notwithstanding section (1), if a manufacturer has made a trade secret claim, the information that is the subject of the trade secret claim will not be posted to the department's website until a determination has been made by the department or, in the case of a manufacturer's appeal, the director, as specified by OAR 836-200-0540.

(3) No information determined by the department or the director to be exempt from disclosure under OAR 836-200-0540 shall be included in the information posted to the department's website.

Statutory/Other Authority: ORS 646A.689

Statutes/Other Implemented: ORS 646A.689

History:

[ID 2-2025, amend filed 03/26/2025, effective 04/01/2025](#)

[ID 1-2020, amend filed 01/29/2020, effective 02/01/2020](#)

[ID 2-2019, adopt filed 02/26/2019, effective 03/01/2019](#)

836-200-0555

Assessments Against Prescription Drug Manufacturers for 2023 and prior

(1) Once annually, no later than October 1, all reporting manufacturers will pay an assessment of \$400. The director may by order reduce the fees assessed for any specific year.

(2) Once annually, no later than October 1, reporting manufacturers that have filed one or more reports under OAR 836-200-0515 to 836-200-053~~32~~ between August 1 of the previous year and July 31 of the current year must pay an additional assessment for each report filed.

(3) For the purposes of section (2), the director shall determine the amount of the assessment by subtracting the revenue collected under section (1) from the amount of revenue needed to cover the department's estimated expenses in administering ORS 646A.689 and OAR 836-200-0500 to 836-200-0550, and dividing the resulting amount by the total number of filings subject to assessment between August 1 of the previous year and July 31 of the current year. The director shall determine the amount of revenue needed by considering the legislatively approved expenditures for administration of ORS 646A.689 and OAR 836-200-0500 to 836-200-0555, as well as the timing of cash revenues and expenditures.

(4) The revenue collected under sections (1) and (2) of this rule must be used solely for expenses incurred in the administration of ORS 646A.689 and OAR 836-200-0500 to 836-200-0555.

(5) A manufacturer must pay each assessment imposed under this rule no later than 30 days after the date of the assessment by the department. A manufacturer must pay interest at nine percent per annum on any assessment that is not paid when due.

(6) Reporting manufacturers shall be subject to the assessment requirements set forth in sections (1) to (5) of this rule for billing periods through July 31, 2023. For billing periods on or after August 1, 2023, reporting manufacturers shall be subject to the annual fee set forth in OAR 836-200-0553.

Statutory/Other Authority: ORS 646A.689

Statutes/Other Implemented: ORS 646A.689

History:

[ID 2-2025, amend filed 03/26/2025, effective 04/01/2025](#)

[ID 14-2024, amend filed 07/31/2024, effective 08/01/2024](#)

[ID 2-2024, minor correction filed 03/20/2024, effective 03/20/2024](#)

[ID 1-2020, amend filed 01/29/2020, effective 02/01/2020](#)

[ID 2-2019, adopt filed 02/26/2019, effective 03/01/2019](#)